Pharmaco - Press Releases

Date	Title	Company
10-Jun-2022	MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022	MorphoSys AG
10-Jun-2022	Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform	Envision Pharma Group
10-Jun-2022	Kinarus Therapeutics Announces Name Change and Commences Trading on the SIX Swiss Exchange under ticker “KNRS”	Kinarus AG
10-Jun-2022	Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency	Biotest AG
09-Jun-2022	PEPperPRINT GmbH Introduces Novel Biomarker Set for Rheumatoid Arthritis Diagnosis at the 13th International Congress on Autoimmunity	B3C newswire
09-Jun-2022	Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic	Biotest AG
08-Jun-2022	CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform	CureVac
08-Jun-2022	CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen	CureVac
08-Jun-2022	Annual General Meeting of Kuros Biosciences approves all resolutions	Kuros Biosciences AG
08-Jun-2022	Cellbox Solutions Releases Its New Product Generation - Cellbox 2.0 - Innovative Portable Incubator Now with Longer Runtime, CFR21/11 Clinical Trial Compatibility and More	Cellbox Solutions
08-Jun-2022	Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab	Tiziana Life Sciences
08-Jun-2022	Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated	Gerresheimer AG
08-Jun-2022	Cellbox Solutions Releases Its New Product Generation - Cellbox 2.0 - Innovative Portable Incubator Now with Longer Runtime, CFR21/11 Clinical Trial Compatibility and More	B3C newswire
08-Jun-2022	Malaria breakthrough. A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite.	Istituto Superiore di Sanità
08-Jun-2022	Parse Biosciences Announces Partnership with Molecular Diagnostics Korea	Parse Biosciences
08-Jun-2022	FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis	Sanofi
08-Jun-2022	Future Digital Award Winners Announced for Digital Health Innovation 2022	Juniper Research
08-Jun-2022	ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study	ImaginAb Inc.
08-Jun-2022	Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers	Ariceum Therapeutics
08-Jun-2022	University of Manchester Adds Carterra’s LSA® Instrument for High-Throughput Antibody Screening and Characterization	University of Manchester